These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22093298)

  • 1. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System.
    Xi B; Wang T; Li N; Ouyang W; Zhang W; Wu J; Xu X; Wang X; Abassi YA
    J Lab Autom; 2011 Dec; 16(6):415-21. PubMed ID: 22093298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.
    Abassi YA; Xi B; Li N; Ouyang W; Seiler A; Watzele M; Kettenhofen R; Bohlen H; Ehlich A; Kolossov E; Wang X; Xu X
    Br J Pharmacol; 2012 Mar; 165(5):1424-41. PubMed ID: 21838757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR
    Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
    Guo L; Coyle L; Abrams RM; Kemper R; Chiao ET; Kolaja KL
    Toxicol Sci; 2013 Dec; 136(2):581-94. PubMed ID: 24052561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility.
    Kirby RJ; Qi F; Phatak S; Smith LH; Malany S
    Toxicol Appl Pharmacol; 2016 Aug; 305():250-258. PubMed ID: 27343406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of extracellular field potential and Ca
    Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
    J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
    Peters MF; Scott CW; Ochalski R; Dragan YP
    Assay Drug Dev Technol; 2012 Dec; 10(6):525-32. PubMed ID: 22574652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.
    Peters MF; Lamore SD; Guo L; Scott CW; Kolaja KL
    Cardiovasc Toxicol; 2015 Apr; 15(2):127-39. PubMed ID: 25134468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements.
    Nguemo F; Šarić T; Pfannkuche K; Watzele M; Reppel M; Hescheler J
    Cell Physiol Biochem; 2012; 29(5-6):819-32. PubMed ID: 22613982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
    Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes.
    Jonsson MK; Wang QD; Becker B
    Assay Drug Dev Technol; 2011 Dec; 9(6):589-99. PubMed ID: 22085047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays.
    Gilchrist KH; Lewis GF; Gay EA; Sellgren KL; Grego S
    Toxicol Appl Pharmacol; 2015 Oct; 288(2):249-57. PubMed ID: 26232523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
    Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.